Krystal Biotech, Inc. KRYS Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
- Krystal Biotech, Inc. (KRYS) reported share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value of $286.11M in Q1 2026.
- How has Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value changed year-over-year?
- Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value increased by 43.9% year-over-year, from $198.81M to $286.11M.
- What is the long-term trend for Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value has grown at a 77.8% compound annual growth rate (CAGR), from $16.8M to $298.66M.